KR20170003745A - Chlorhexidine antiseptic for smallanimal - Google Patents
Chlorhexidine antiseptic for smallanimal Download PDFInfo
- Publication number
- KR20170003745A KR20170003745A KR1020150092611A KR20150092611A KR20170003745A KR 20170003745 A KR20170003745 A KR 20170003745A KR 1020150092611 A KR1020150092611 A KR 1020150092611A KR 20150092611 A KR20150092611 A KR 20150092611A KR 20170003745 A KR20170003745 A KR 20170003745A
- Authority
- KR
- South Korea
- Prior art keywords
- chlorhexidine
- small animal
- surfactant
- effect
- test
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Abstract
Description
The present invention relates to a small animal therapeutic agent using chlorhexidine. More specifically, the present invention provides a sterilization effect and an antifungal effect of a small animal, and unlike the disinfectant used in the past, Chlorhexidine, which is the main ingredient, is distributed for human use on the market, and its safety and efficacy are certified and can be used for animals. Especially, it can be used for veterinary medicine and small animals using chlorhexidine It is about the cure.
It is an environmental hormone known to be especially harmful to children, which is an insecticide and causes dermatitis, eye pain, digestive system stimulation and the like.
In addition, it has been widely used in companion animals and small animals to cause side effects (mucous membrane irritation, headache, nausea, dizziness, elevated blood pressure, wastewater, generalized convulsions).
However, chlorhexidine (CHG), on the other hand, does not cause any problems in humans or small animals, and its stability and efficacy are already known. Chlorhexidine has a germicidal and bacteriostatic action against Gram-negative bacteria and Gram-positive bacteria in a wide range. This material is a bisbiguanide substance and is widely used as acetate, glucuronate salt and hydrochloride.
The chemical name is mainly composed of 1,1'-hexamethylene bis [5- (4-chlorophenyl) biguanide] acetate digluconate and dihydrochloride salts and is stabilized with each organic acid salt.
Among them, the most stable substance tested as organic acid salt is glucuronate salt, which is widely used as a sterilizing preservative. It has a strong sterilizing action at high concentration and a high concentration of Pseudomonas sp. But also exhibits excellent bacteriostatic action against these strains. Commercially, the glucuronate salt is a 20% aqueous solution and its standard is listed in the pharmacopoeia worldwide.
However, depending on the proper concentration of hydrogen ion and the content of aqueous solution, there is a strong antiviral action and a definite effect on fungi and fungi, and the effect of alcohols and mixtures is improved.
The optimal effect of this chlorhexidine preparation is that it is effective at weakly acidic or neutral pH, and when it is not possible to use alcohols for use, other surfactants or germicidal auxiliaries are used as adjunctive agents within the range except for the formula It is filed.
Australian Patent No. 459,343 describes a skin cleanser comprising a salt in which chlorhexidine is combined with a polyoxyethylene-polyoxypropylene block copolymer, which is a low foaming, nonionic surfactant, When adding a foaming promoter such as an alkylamine oxide into a contained composition, it is necessary to bond the polymer at a high ratio of about 20-25% in order to provide a sufficient degree of foaming as expected from this type of product.
Korean Patent Publication No. 92-006539 (Aug. 8, 1992) discloses a water-soluble salt of chlorhexidine and a compound represented by the structural formula (I)
RO - (- CH2CH2O-) nOH (I)
Wherein R is an alkylphenol, a fatty alcohol or a fatty acid, n is such a number as to be soluble in water at a temperature of from room temperature to 45 ° C, particularly 8.5 to 15 moles per molecule when R is nonylphenoxy Which is the best detergent for biological materials and surfaces.
≪ / RTI > is disclosed.
U.S. Patent No. 5,908,865 also discloses that chlorhexidine gluconate and the following moieties
The polycarboxylic acid represented by Breakfast (I)
HOOC- (CR ' R ' 2) n-COOH (I)
Wherein n is an integer from 1 to 3; I is a positive integer not greater than n; Ri1 and Ri2 are each independently H, -OH or -COOH when n is 1, provided that not all are simultaneously H; R11, R12 and R22 are H, -OH or -COOH when n is 2, provided that not all of them are simultaneously H, and each of R11, R12, R21, R22, R31 and R32 is H, OH or -COOH, but in any case two adjacent carbons do not have a total of four hydrogens.
≪ / RTI >
The solubility of the hydrochloride, acetate and glucuronate salts of chlorhexidine, which are the three salts of chlorhexidine, is poorly understood and unrecognized by chemical researchers. The hydrochloride, which is considered to be the most soluble, It is sparingly soluble in almost water-insoluble water. Propylene glycol is not soluble in universal solubilizer, so it can not be used as a water-soluble preparation.
The stability is confirmed by a single cycle of freezing thawing test (-20 ° C to room temperature), which is observed at low temperature due to incompleteness of the formation of sediment at room temperature. Although chlorhexidine acetate salt is slightly more soluble than hydrochloride in glycerin or propylene glycol than hydrochloride in water, it is still insoluble in water. Fortunately, it dissolves well in ethanol, which is alcohol. However, it is used as a buffer solution to precisely adjust hydrogen ion concentration Baxter company in Europe, famous for its disinfectant, has launched as an aqueous solution.
However, they are not releasing an aqueous solution of 0.5% chlorhexidine gluconic acid salt and are releasing it as an acetate salt. This is because the chlorhexidine aqueous solution is insecure and it is intended to circulate products that are always reliable as a global fungicide manufacturing company.
Chlorhexidine gluconate salts are soluble in water and alcohol (ethanol) in a 20% aqueous solution (Miscible with water).
And the 5% aqueous solution has pH 5.5 ~ 7.0, which is the hydrogen ion region with excellent sterilizing power.
The glucuronate salt is also used as a mouthwash and mouthwash in the mouth. Despite these advantages, the disadvantage is that citric acid salts, which are precipitated in aqueous solution, water, hard water, isotonic solution and the like, and used as a buffer solution, reduce the influence of chlorine ions, but still have a problem.
Thus, in Korean Patent Publication No. 92-006539, citric acid buffer solution can not be used. U.S. Patent No. 5,908,865 discloses a polycarboxylic acid (phenylamine maleic acid derivative) that can coexist with citrate salts (such as sodium salt) and is stable and does not precipitate while coexisting with a chloride (Cl-) salt. (Senju Pharmaceutical Co., Ltd), a Japanese pharmaceutical company.
However, these polycarboxylic acids have been evaluated as excellent, but they are described as being best when the amount of the polycarboxylic acids is almost the same as the content of chlorhexidine. A small amount of the polyoxycarboxylic acid remaining in the endoscopic instrument is undesirable from the viewpoint of the inventors and the general evaluation .
The occurrence of such a problem is avoided when a preparation is required only as an aqueous solution of chlorhexidine, that is, in the case of a final irrigation of an endoscopic flow while avoiding irritating solvents such as alcohol (ethanol, isopropyl alcohol), and washing using sterilized distilled water, sterilized purified water, The use of low-concentration chlorhexidine gluconate solution in the hospital has been increasingly used to ensure more reliable endoscopy disinfection by the hospital as a means to confirm once more immediately before that.
This is due to the FDA Guideline, which has recently strengthened the sterilization control of endoscopy devices and vascular catheters in the United States and the advance sterilization of skin at the injection site. Other inventors have made preparations by adding cetylpyridinium chloride to chlorhexidine as an auxiliary disinfectant (eg Martindale 31th. 1993. 789-790 page) and recently also used Cetrimide.
This is because the chlorhexidine gluconate preparation, which is most stable in the case of aqueous solution formulation, is occasionally precipitated by the chloride (Cl) ion in the isotonic solution. This means that in case of aqueous solution, care should be taken when using it as an isotonic solution. In case of using sterilized distilled water or diluted sterile purified water, dilute the concentrated stock solution, which becomes the preparation solution Belongs.
In recent years, as the hospital work has been rapidly diversified and many hospitals have accumulated, hospitals are demanding easy and stable aqueous solution formulations. In order to solve this problem, the inventors of the present invention have been able to very effectively remove residual blood and body fluids, which are most frequently pointed as pollutants in the endoscope, by grasping the essence of the sterilization base of the endoscopic instrument based on the experience of long time manufacturing and development of the sterilizing agent of the endoscopic instrument (Aminoethyl) glycine hydrochloride, which is a drug used in combination with chlorhexidine gluconate solution in a very small amount, was found to be excellent, and the present invention was completed.
SUMMARY OF THE INVENTION The present invention has been made in view of the above-described problems in the prior art, and it is an object of the present invention to provide an aqueous solution composition, wherein Citric acid salts which are precipitated and used as a buffer solution in water, water, isotonic solution, It is an object of the present invention to provide a therapeutic agent for small animal using chlorhexidine which is safe by supplementing the disadvantage of chlorhexidine gluconate which reduces the influence of chlorine ion but still has a problem in stability.
As a means for achieving the above object, the present invention relates to a method for producing chlorosilane, which comprises reacting chlorhexidine glucuronate with RNHCH2CH2NHCH2CH2NHCH2COOH HCl (I) represented by the following structural formula (I)
Wherein R is a carbon number of 12 or 14. (W / V) of chlorhexidine gluconate and 0.001 to 0.1% (W / V) of a bilayer surfactant compound having the structural formula (I), and a polysorbate surfactant Bait (Tween 80).
And further contains 0.01 to 0.05% (W / V) of polysorbate (Tween 80) as a surfactant, and further contains an alkali metal salt of citric acid for adjusting the hydrogen ion concentration.
According to the small animal therapeutic agent using chlorhexidine of the present invention,
First, chlorhexidine is used to exhibit the bactericidal effect and the fungicidal effect of small animals. Unlike the conventional disinfectant, it is economically effective because it has excellent sterilizing effect and fungicidal effect even when used in small amounts.
Second, it is distributed for the human body, and its safety and effectiveness are certified, and even if it is used for animals, it has many effects.
Third, there is an excellent effect in sterilization of disinfection and surgical instrument disinfection of animal hospital medical staff and various small animal skin.
Since the present invention contains chlorhexidine, unlike conventional disinfectants, it has excellent fungicidal and disinfecting effects against small animals even if only a small amount is used.
The main component, chlorhexidine, has been approved for stability and efficacy, and can be used for animals. In particular, disinfection and disinfection of surgical vials are possible for veterinarian medical staff and small animal skin.
Advantages of the present invention will be described as follows.
1. By reducing the amount of CHG as a main ingredient and ADAG as an auxiliary ingredient, it shows sterilizing power equal to that of conventional compositions, and it is possible to sterilize the whole body of the veterinarian, nurse and small animal, disinfect the skin, disinfect the endoscope and catheter, Indicates effective effect on site.
2. Chlorhexidine aqueous solution does not form CHG precipitation during long-term storage at low temperature.
3. The addition of hydrogen ion buffers (eg citrate salts) in aqueous solutions also reduces the tendency for CHG to precipitate.
4. The amount of chlorhexidine used is reduced and the amount of total precipitation is reduced, which is economical.
5. Decrease the use of two kinds of substances, and show remarkable antifungal effect at the level of 0.5% CHG and 0.01% aqueous ADAG solution.
The present invention also provides a method for stabilizing an aqueous solution preparation containing chlorhexidine and a composition for increasing sterilizing power.
The material used in the present invention is an alkyldi (aminoethyl) glycine hydrochloride {Alkyl di (aminoethyl) glycine hydrochloride
RNHCH2CH2NHCH2CH2NHCH2COOH HCl (I)
Wherein R is a carbon number of 12 or 14.
Molecular formula is C18H39O2N3 HCl positive (acid, alkali, amphoteric surfactants) surfactant, a safe disinfectant used as a soft contact lens cleaning agent, and is an important industrial material widely used as an additive in the cotton fabric antifungal and water treatment agent fermentation industries . The foreign substance is a 30% aqueous solution standard. (Contact lens cleaner: patent USA.Pat. 6,177,480, USA Pat.7,364,723)
On the other hand, chlorhexidine (abbreviated as CHG) can not penetrate into the walls or skin of the gastrointestinal tract and has insufficient retentivity. Therefore, the sterilizing power is lowered against bacteria that penetrate deeply into the surface of skin or endoscope, but the alkaline aminoglycine derivative as an amphoteric surfactant, The effect is enhanced by the sterilizing power and the effect of precipitation is suppressed because it contributes to the stability of the aqueous solution of chlorhexidine and its salt, that is, the glucuronate salt, in stability.
This is a result of the test which is clearly shown in the preparation test, and the precipitation did not occur even after being left for a long time.
Although ADAG was used in small doses, it has been found that chlorhexidine has a powerful sterilizing power against bacterial spores by complementing the problem of less effect on bacterial spores.
The composition of the present invention may be prepared by a conventional aseptic filtration method and sterilized purified water.
By using chlorhexidine as a main component and ADAG as an auxiliary component, it acts only as an additive. It is a mutually optimal combination because it minimizes the adverse effects on the skin of injured small animals and also reduces the amount of chlorhexidine.
In the present invention, the concentration of the two substances is preferably 0.01 to 5% (W / V) of CHG and 0.001 to 0.1% (W / V) of ADAG, preferably 0.05 to 1% of CHG and 0.005 to 0.03 of ADAG Preferably, CHG 0.5% (W / V) and ADAG 0.01% (W / V) are optimum.
In the present invention, polysorbate (Tween 80), which is a surfactant, may be further contained, and polysorbate (Tween 80) used at this time may be contained in the range of 0.01 to 0.05% (W / V).
The present invention may further contain an alkali metal salt of citric acid to adjust the hydrogen ion concentration.
On the other hand, examples of preparation and test of the composition showing the effect recorded in the beginning are described in more detail by the following comparative examples, examples and experimental examples.
Although the sterilizing power depends on the amount of the following composition and the preparation of the composition, the combination of the CHG material and the ADAG material provides a great deal of effectiveness. The 0.5% chlorhexidine gluconic acid solution thus prepared had a pH of 6.52 to 6.55 and an Sg. 0.9998.
Examples of this reaction were carried out as follows, and the total liquid was proportionally set to an even volume of 100 ml to prepare and test.
Comparative Example 1
Comparative composition
Chlorhexidine digluconate 20% (W / V) 2.5 ml
Polysorbate 80 (Tween 80) 0.1 g
Isopropyl alcohol 0.4ml
Lavender flavor 0.01g
KFDA specification tar color red No. 40 0.005g
The purified water was added in an appropriate amount
Mix thoroughly to make the total volume to 100 ml.
Comparative Example 2
Comparative composition
Chlorhexidine digluconate 20% (W / V) 2.5 ml
Polyoxyethylene polyoxypropylene glycol 0.1 g
Isopropyl alcohol 0.4ml
Lavender flavor 0.01g
KFDA specification tar color red No. 40 0.005g
The purified water was added in an appropriate amount
Mix thoroughly to make the total volume to 100 ml.
Comparative Example 3
Comparative composition
Chlorhexidine digluconate 20% (W / V) 2.5 ml
0.1 g of nonylphenol ethoxylate
Isopropyl alcohol 0.4ml
Lavender flavor 0.01g
KFDA specification tar color red No. 40 0.005g
The purified water was added in an appropriate amount
Mix thoroughly to make the total volume to 100 ml.
Comparative Example 4
Comparative composition
Chlorhexidine digluconate 20% (W / V) 2.5 ml
0.01 g of maleic acid
Polysorbate 80 (Tween 80) 0.1 g
Isopropyl alcohol 0.4ml
Lavender flavor 0.01g
KFDA specification tar color red No. 40 0.005g
The purified water was added in an appropriate amount
Mix thoroughly to make the total volume to 100 ml.
Example 1
The composition of the present invention
Chlorhexidine digluconate 20% (W / V) 2.5 ml
Lauryldiaminoethylglycine hydrochloride solution
0.034 ml (0.0347 g) of 30% (W / V) (Sg.1.0201) (compound of formula I)
Polysorbate (Tween 80) 0.1 g
Isopropyl alcohol 0.4 ml
Lavender flavor 0.01g
KFDA specification tar color red No. 40 0.005g
The purified water was added in an appropriate amount
Mix thoroughly to make the total volume to 100 ml.
Example 2
The composition of the present invention
Chlorhexidine digluconate 20% (W / V) 2.5 ml
Lauryldiaminoethylglycine hydrochloride solution
30% (W / V) (Sg. 1.0201) (compound of formula I) 0.068 g
Polysorbate (Tween 80) 0.1 g
Isopropyl alcohol 0.4 ml
Lavender flavor 0.01g
KFDA specification tar color red No. 40 0.005g
The purified water was added in an appropriate amount
After homogeneous mixing, the total volume is made 100 ml.
Example 3
The composition of the present invention
Chlorhexidine digluconate 20% (W / V) 2.5 ml
Lauryldiaminoethylglycine hydrochloride solution
30% (W / V) (Sg. 1.0201) (compound of formula I) 0.017 g
Polysorbate (Tween 80) 0.1 g
0.4 ml of isopropanol
Lavender flavor 0.01g
KFDA specification tar color red No. 40 0.005g
The purified water was added in an appropriate amount
After homogeneous mixing, the total volume is made 100 ml.
Experimental Example 1
Single cycle of freezing thawing test (SCFT test, single-20C ~ room temperature sea ice test)
As a result of conducting a stability test for the temperature change of general pharmaceuticals, the turbidity after thawing was excellent in the composition of Example 2, and the composition of Example 1 was also excellent Respectively.
In general, the formulation containing lauryldiaminoethylglycine hydrochloride was stable. It is preferable to select the composition of Example 1 which is safe because the degree of each animal is different for skin irritation. The compositions of the comparative examples and the examples showed no significant difference in the thawing speed as a result of the SCFT test, and thawing was earlier than that of the purified water.
Also, when the sedimentation continued to appear after thawing, the compositions prepared in Examples were excellent.
Experimental Example 2
Microbial growth inhibition test and sterilization test
Test method: Tested according to the Korea Food & Drug Administration Notification No. 2008-13, Dilution Neutralization Test.
The results are shown in Table 1 below.
Microbial growth inhibition test and sterilization test
As shown in Table 1, the results of the microbial growth inhibition test and the sterilizing power test of the compositions prepared in Examples 1 to 3 are excellent.
Experimental Example 3
Stability test of microorganism pollution degree of medicine
As a result of the microbial limit tests on the compositions obtained in the respective comparative examples and examples, no contamination was observed at the observation up to 6 months, and no bacteria, fungi, E. coli, P. aeruginosa, S. aureus or Salmonella were detected.
Experimental Example 4
Change test of drug content test
As a result of performing a chlorhexidine labeling content test for 6 months after the production, the compositions obtained in the comparative examples and the examples were deviated from the standard or were out of the range.
Claims (2)
RNHCH2CH2NHCH2CH2NHCH2COOH HCl (I)
Wherein R is a carbon number of 12 or 14.
Containing surfactant as an active ingredient,
(W / V) of chlorhexidine gluconate and 0.001 to 0.1% (W / V) double-side surfactant compounds of formula (I)
A therapeutic agent for small animals using chlorhexidine further containing polysorbate (Tween 80) as a surfactant.
, And 0.01 to 0.05% (W / V) of polysorbate (Tween 80) as a surfactant,
A therapeutic agent for small animal using chlorhexidine further containing an alkali metal salt of citric acid for adjusting the hydrogen ion concentration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150092611A KR20170003745A (en) | 2015-06-30 | 2015-06-30 | Chlorhexidine antiseptic for smallanimal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150092611A KR20170003745A (en) | 2015-06-30 | 2015-06-30 | Chlorhexidine antiseptic for smallanimal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170003745A true KR20170003745A (en) | 2017-01-10 |
Family
ID=57811778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150092611A KR20170003745A (en) | 2015-06-30 | 2015-06-30 | Chlorhexidine antiseptic for smallanimal |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20170003745A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019075180A3 (en) * | 2017-10-12 | 2019-06-13 | Medline Industries, Inc. | Antiseptic wipes |
-
2015
- 2015-06-30 KR KR1020150092611A patent/KR20170003745A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019075180A3 (en) * | 2017-10-12 | 2019-06-13 | Medline Industries, Inc. | Antiseptic wipes |
| US11369549B2 (en) | 2017-10-12 | 2022-06-28 | Medline Industries, Lp | Antiseptic wipes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9750755B2 (en) | Antimicrobial compositions and related methods | |
| CN101137357B (en) | Antimicrobial compositions comprising esters of hydroxycarboxylic acids | |
| CA2550929C (en) | Antiseptic compositions, methods and systems | |
| AU2013364412B2 (en) | Germicidal compositions comprising carboxylic acid mixture and use as topical disinfectants | |
| ES2546111T3 (en) | Composition of improved biocidal hydrogen peroxide low foam | |
| JP2007536233A (en) | Treatment with polycationic antibacterial drugs | |
| US9693564B2 (en) | Water based antimicrobial composition using benzalkonium chloride and cocamidopropyl PG-dimonium chloride phosphate | |
| AU2006259757A1 (en) | Compositions and methods of use | |
| ES2829283T3 (en) | Antimicrobial and cleansing composition consisting of a polymeric biguanide and EDTA | |
| JPH09278610A (en) | Composition for controlling harmful microorganism | |
| KR101093992B1 (en) | Aqueous compositions for disinfection and/or sterilization | |
| KR20170003745A (en) | Chlorhexidine antiseptic for smallanimal | |
| EP1634589B9 (en) | Aqueous olanexidine solution, method of preparing the same, and disinfectant | |
| JP2540777B2 (en) | Liquid disinfectant | |
| KR101350442B1 (en) | A stable antimicrobial and antiseptic aqueous composition containing chlorhexidine | |
| CN107646862B (en) | Olanexidine aqueous solution based on ascorbic acid and preparation method and application thereof | |
| JP2022506394A (en) | Compositions for treating biofilms without inducing drug resistance | |
| JP7486557B2 (en) | Semi-solid composition for preventing bacterial contamination - Patents.com | |
| CN113163754B (en) | Stable iodine-containing antimicrobial teat dip compositions | |
| RU2499610C2 (en) | General method for air, fluid and surface cleansing with biocompatible microporous silicon for decontamination of viruses in household use, medicine and industries | |
| ES2300217B1 (en) | COMPOSITION FOR THE TREATMENT OF UBRES IN MAMMALS AFTER MILKING. |